Alzheimer's Disease

Neurotechnology company, Grey Matter Neurosciences, announced it secured $14 million in seed financing, which will be used to develop an ultrasound headset for individuals with Alzheimer's disease and test that device in clinical trials.

The analytical tool can also predict demographics and understand personality traits by understanding brain activity patterns.